RecruitingNCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
Sponsor
Camurus AB
Enrollment
200 participants
Start Date
Jun 5, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Have started or will be starting treatment with octreotide SC depot for acromegaly
Exclusion Criteria2
- Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly
- Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOctreotide subcutaneous depot
Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07583563
Related Trials
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT0693062571 locations
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
NCT004611883 locations
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
NCT0703742045 locations
Study of MAR002 in Healthy Men
NCT071951751 location
Effects of Pasireotide Lar Therapy on Bone Metabolism
NCT071799261 location